# Aura Biosciences, Inc.: overview

AURA · Nasdaq · CIK 1501796 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/aura.md) · [Financials](/companies/aura/financials.md) · [Filings](/companies/aura/filings.md) · [Insiders](/companies/aura/insiders.md)

Revenue is not reported in this company’s XBRL financial statements.

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(0.42)](/filings/0001193125-25-278817.md) | not reported | [(0.55)](/filings/0001193125-26-216808.md) | [(0.47)](/filings/0001193125-26-343429.md) | [(0.40)](/filings/0001193125-25-278817.md) | not reported | [(0.50)](/filings/0001193125-26-216808.md) | [(0.48)](/filings/0001193125-26-343429.md) |
| Free cash flow | $m | [(15.6) d](/filings/0001193125-25-278817.md) | [(24.3) d](/filings/0001193125-26-130401.md) | [(23.5)](/filings/0001193125-26-216808.md) | [(20.8) d](/filings/0001193125-26-343429.md) | [(20.2) d](/filings/0001193125-25-278817.md) | [(20.6) d](/filings/0001193125-26-130401.md) | [(30.0)](/filings/0001193125-26-216808.md) | [(32.5) d](/filings/0001193125-26-343429.md) |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(8.95)](/filings/0000950170-23-008166.md) | [(1.96)](/filings/0000950170-24-036814.md) | [(1.93)](/filings/0000950170-25-043943.md) | [(1.75)](/filings/0001193125-26-130401.md) | [(1.76)](/filings/0001193125-26-130401.md) |
| Free cash flow | $m | [(34.5)](/filings/0000950170-23-008166.md) | [(55.7)](/filings/0000950170-24-036814.md) | [(64.6)](/filings/0000950170-25-043943.md) | [(81.1)](/filings/0001193125-26-130401.md) | [(85.2)](/filings/0001193125-26-130401.md) |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/aura/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [TCG Crossover Management, LLC](/funds/1839948.md) | 2026-06-30 | $67.7m | 9,533,333 |  | New +9,533,333 |
| [MONTANOVA CAPITAL, LLC](/funds/1569064.md) | 2026-06-30 | $51.2m | 7,206,217 |  | Added +2,833,333 |
| [Frazier Life Sciences Management, L.P.](/funds/1892134.md) | 2026-06-30 | $50.4m | 7,100,000 |  | Added +2,000,000 |
| [Long Focus Capital Management, LLC](/funds/1602716.md) | 2026-06-30 | $36.3m | 5,119,582 |  | Added +500,000 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $33.4m | 4,707,674 |  | Added +1,121,034 |
| [ADAGE CAPITAL PARTNERS GP, L.L.C.](/funds/1165408.md) | 2026-06-30 | $32.9m | 4,640,000 |  | Reduced −241,125 |
| [Caligan Partners LP](/funds/1727492.md) | 2026-06-30 | $30.5m | 4,298,248 |  | Added +4,068,384 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $29.1m | 4,100,342 |  | Added +1,856,514 |
| [FCPM III SERVICES B.V.](/funds/2013410.md) | 2026-06-30 | $28.8m | 4,053,775 |  | New +4,053,775 |
| [ORBIMED ADVISORS LLC](/funds/1055951.md) | 2026-06-30 | $23.7m | 3,333,333 |  | New +3,333,333 |

## Recent filings

[All 375 filings](/companies/aura/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-11 | 07:15 ET | [10-Q](/filings/0001193125-26-343429.md) | Quarterly report, period 2026-06-30 | 0001193125-26-343429 |
| 2026-08-11 | 07:05 ET | [8-K](/filings/0001193125-26-343408.md) | 2.02 Results of operations; 2.05 Exit or disposal costs; 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-343408 |
| 2026-08-05 | 16:15 ET | [8-K](/filings/0001193125-26-335157.md) | 5.07 Shareholder vote results | 0001193125-26-335157 |
| 2026-07-08 | 07:17 ET | [8-K](/filings/0001193125-26-297992.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-297992 |
| 2026-06-29 | 17:28 ET | [DEF 14A](/filings/0001193125-26-288498.md) | Proxy statement, period 2026-08-05 | 0001193125-26-288498 |
| 2026-06-11 | 16:31 ET | [8-K](/filings/0001193125-26-267676.md) | 5.07 Shareholder vote results | 0001193125-26-267676 |
| 2026-05-11 | 16:15 ET | [10-Q](/filings/0001193125-26-216808.md) | Quarterly report, period 2026-03-31 | 0001193125-26-216808 |
| 2026-05-11 | 16:15 ET | [SCHEDULE 13D/A](/filings/0000950142-26-001345.md) | Ownership report, active investor, amended | 0000950142-26-001345 |
| 2026-05-11 | 16:05 ET | [8-K](/filings/0001193125-26-216743.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-216743 |
| 2026-05-05 | 17:21 ET | [8-K](/filings/0001193125-26-206804.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-206804 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-130401.md), filed Mar 30, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1501796
- Tickers: AURA
- Exchange: Nasdaq
- SIC code: 2836 Biological Products, (No Diagnostic Substances)
- State of incorporation: DE
- Filer category: Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 17:26 ET. No prices; not investment advice.